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Long-term glucocorticoid treatment is associated with numerous adverse outcomes, including weight gain, 
insulin resistance, and diabetes; however, the pathogenesis of these side effects remains obscure. Glucocor-
ticoids also suppress osteoblast function, including osteocalcin synthesis. Osteocalcin is an osteoblast-spe-
cific peptide that is reported to be involved in normal murine fuel metabolism. We now demonstrate that 
osteoblasts play a pivotal role in the pathogenesis of glucocorticoid-induced dysmetabolism. Osteoblast-tar-
geted disruption of glucocorticoid signaling significantly attenuated the suppression of osteocalcin synthesis 
and prevented the development of insulin resistance, glucose intolerance, and abnormal weight gain in cor-
ticosterone-treated mice. Nearly identical effects were observed in glucocorticoid-treated animals following 
heterotopic (hepatic) expression of both carboxylated and uncarboxylated osteocalcin through gene therapy, 
which additionally led to a reduction in hepatic lipid deposition and improved phosphorylation of the insulin 
receptor. These data suggest that the effects of exogenous high-dose glucocorticoids on insulin target tissues 
and systemic energy metabolism are mediated, at least in part, through the skeleton.
Introduction
Glucocorticoids have been used as a therapeutic agent for over 60 
years, with significant beneficial outcomes in terms of treating 
chronic inflammatory conditions such as rheumatoid arthritis, 
asthma, or inflammatory bowel disease (1, 2). Glucocorticoids 
are also widely used as cancer therapeutics, for hematological 
conditions, and in posttransplant management (3). However, par-
ticularly when given at higher doses and for extended periods of 
time, glucocorticoids are associated with multiple and potentially 
debilitating adverse outcomes, which are often chronic in nature 
and difficult to treat. These include, but are not limited to, muscu-
loskeletal pathologies such as osteoporosis (4) and sarcopenia (5); 
metabolic disorders such as glucose intolerance, diabetes mellitus, 
and dyslipidemia (6, 7); and excessive and abnormal fat accrual (6).
The effects of exogenous glucocorticoids on bone and bone cells 
have been relatively well established (8, 9). It is understood that glu-
cocorticoids affect the function of all 3 cell types, osteoblasts, osteo-
clasts, and osteocytes (8, 10), with most of the evidence indicating 
that osteoblasts are the main skeletal target (10, 11). In humans, 
the effects of glucocorticoids on the skeleton and particularly the 
osteoblast are manifested by a rapid and profound suppression of 
serum markers of bone formation, which correlates with bone loss 
over time (12). For example, serum levels of osteocalcin, a marker of 
osteoblast activity (13), are invariably reduced in patients receiving 
glucocorticoids, even when given at lower doses (12, 14). It has also 
been documented that glucocorticoids induce an initial stimula-
tion in bone resorption via increases in osteoclastogenesis (8, 15) 
as well as matrix metallo proteinases (15).
In contrast to these well-documented skeletal effects, the cellular 
and molecular pathways by which exogenous glucocorticoids exert 
their detrimental effects on energy and particularly glucose metabo-
lism are less well established (16). Thus, while we know that many (but 
not all) patients receiving glucocorticoids develop impaired glucose 
tolerance or even type 2 diabetes (16), it remains unclear exactly how 
glucocorticoids affect the regulation of fuel metabolism on a molecu-
lar and cellular basis. As a result, clinicians are unable to predict which 
patients will become glucose intolerant or diabetic, and there are not 
any known strategies to directly prevent these unwanted outcomes.
Osteocalcin is a noncollagenous protein that is unique in that 
it is synthesized and secreted solely by osteoblasts and under-
goes vitamin-K–dependent posttranslational modifications via 
γ-carboxylation of 3 glutamic acid residues (13, 17). Carboxylated 
osteocalcin has a high affinity for binding to the mineralized bone 
matrix. Studies have failed to confirm osteocalcin as a functional 
contributor to the initial deposition of mineral (18); however, it 
does affect the growth and maturation of the hydroxyapatite crys-
tals. Other studies suggest that osteocalcin plays a role in bone 
remodeling (19, 20). In humans, osteocalcin is incompletely car-
boxylated and therefore circulates in both a fully carboxylated and 
undercarboxylated or uncarboxylated form (21).
Recent mouse data suggests that osteocalcin may be involved in 
the control of fuel metabolism via its actions on pancreatic insulin 
production and secretion as well as insulin sensitivity (22–24). In 
particular, uncarboxylated osteocalcin has been suggested to act in 
a hormone-like manner to control energy metabolism (22, 25). The 
authors indicate that uncarboxylated osteocalcin is responsible for 
the metabolic actions that they report on pancreatic β cells and 
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insulin-sensitive tissues. These results provide further evidence 
that the skeleton, through specific products such as osteocalcin, 
may have an active role in the control of fuel metabolism under 
normal physiological conditions. Here, we demonstrate that the 
skeleton and, in particular, mature osteoblasts play a pivotal role 
in the pathogenesis of glucocorticoid-induced metabolic disor-
ders. Our data are derived from two experimental approaches. 
First, we used a transgenic mouse model in which intracellular 
glucocorticoid signaling is disrupted at the prereceptor level exclu-
sively in osteoblasts (26, 27). This enabled us to study the effects 
of glucocorticoid signaling in osteoblasts on whole-body fuel 
metabolism, using the same dose of glucocorticoids that we have 
previously shown to suppress bone formation (10). Second, we 
induced endogenous heterotopic expression of carboxylated and 
uncarboxylated osteocalcin by gene therapy in WT mice in order 
to determine whether osteocalcin is able to prevent, attenuate, or 
reverse glucocorticoid-induced metabolic dysfunction in our mice.
Results
Prevention of glucocorticoid-induced metabolic dysfunction  
via targeted transgenic inactivation of glucocorticoid  
signaling in osteoblasts
Transgenic (Tg) overexpression of the glucocorticoid-inactivating 
enzyme 11β-hydroxysteroid dehydro genase type 2 (11bHSD2) 
under the control of the rat 2.3-kb collagen type I promoter results 
in disruption of prereceptor glucocorticoid signaling in osteoblasts 
of Col2.3-11bHSD2 Tg mice and the development of a distinct 
skeletal phenotype (26–28). To test the hypothesis that the met-
abolic effects of exogenous glucocorticoids are mediated through 
the osteoblast, Col2.3-11bHSD2 Tg mice and their WT littermates 
were treated with 1.5 mg corticosterone (slow-release pellet) per 
week, or placebo, for 28 days, and phenotypic and functional met-
abolic parameters were monitored over time or at end point. Both 
WT and Tg mice were implanted with corticosterone pellets. Cor-
ticosterone is the major active circulating glucocorticoid in mice. 
Clearly elevated levels of corticosterone were present in mouse 
serum within 3 days of treatment onset. Serum levels of corticos-
terone peaked at 536 ± 85 nmol/l and 489 ± 79 nmol/l in corti-
costerone-treated WT and Tg mice, respectively, while remaining 
within the rodent-specific reference range in placebo-treated WT 
and Tg animals (149 ± 43 nmol/l and 171 ± 37 nmol/l, respectively).
Disruption of osteoblastic glucocorticoid signaling attenuates glucocorti-
coid-induced obesity and hyperlipidemia. As expected, all mice treated 
with corticosterone displayed an initial drop in body weight. WT 
mice treated with corticosterone gained significantly more weight 
than WT placebo-treated controls (P < 0.05; Figure 1A). By day 
28, corticosterone-treated WT mice had gained 4.1 grams in total 
body weight, compared with 2.5 grams in WT controls. The latter 
would be considered normal growth-associated weight gain. In 
Figure 1
Targeted disruption of glucocorticoid signaling in osteoblasts profoundly affects glucocorticoid-induced changes in body composition and blood 
lipids. (A) End point (day 28) body weight of WT and Tg mice treated with 1.5 mg corticosterone (1.5 mg GC) per week or placebo. (B) Body weight 
of treated WT and Tg mice over the 4-week period. (C) Fat mass in WT and Tg mice at day 28 measured by dual-energy x-ray absorptiometry. 
(D) Adipose cells per mm2 in H&E-stained sections of gonadal fat pads following 28 days of treatment. (E) Serum triglyceride levels of treated 
WT and Tg mice over the 4-week period. (F) Serum cholesterol levels of treated WT and Tg mice over the 4-week period. *P < 0.05, #P < 0.01, 
†P < 0.001 compared with respective genotype placebo-treated controls; ‡P < 0.05, **P < 0.01, ##P < 0.001 WT 1.5 mg GC compared with Tg 1.5 
mg GC (2-way ANOVA followed by post-hoc analysis; repeated-measures ANOVA followed by post-hoc analysis for time-dependent measure-
ments; error bars represent SEM).
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contrast, body weight at day 28 did not differ between untreated 
and corticosterone-treated Col2.3-11bHSD2 Tg mice (Figure 1, A 
and B), with both untreated and treated Tg mice having gained 3.3 
and 3.0 grams, respectively, in total body weight. Compared with 
placebo-treated WT mice, body weight at end point was slightly 
lower in both treated and untreated Tg mice, consistent with the 
known smaller body size of Col2.3-11bHSD2 Tg mice observed 
in previous studies (26, 28). WT mice treated with corticosterone 
gained a significantly greater amount of weight than the Tg mice 
compared with that of their placebo-treated WT controls. This was 
observed by day 28 (P < 0.05; Figure 1B).
Body fat mass, as measured by dual-energy x-ray absorptiometry, 
was significantly increased in corticosterone-treated mice com-
pared with that in placebo-treated WT mice, while being similar in 
placebo-treated WT and Tg mice and in corticosterone-treated Tg 
animals (Figure 1C). We further characterized the adipose tissues 
by measuring adipocyte numbers (cells/mm2) in H&E-stained sec-
tions of gonadal fat pads excised from mice following 28 days of 
corticosterone or placebo treatment. We observed that corticoster-
one-treated WT mice had significantly fewer cell numbers per mm2 
than placebo-treated controls. In contrast, the small difference in 
cell number seen between placebo- and corticosterone-treated Tg 
mice was not statis tically significant (Figure 1D). These results sug-
gest that cell size was increased in corticosterone-treated WT mice.
Serum triglyceride levels rose significantly in corticoster-
one-treated WT mice by day 7 and remained significantly higher 
than both the starting levels on day 0 and the levels of place-
bo-treated controls from day 7 until day 28. In contrast, corticoster-
one-treated Tg animals remained at levels similar to and not signifi-
cantly different from the placebo groups (Figure 1E). There was no 
overall effect of genotype on triglyceride levels and no interaction 
between genotype and treatment, as analyzed by a 2-way ANOVA. Tg 
mice also displayed a delayed increase in serum cholesterol follow-
ing corticosterone treatment over the 28 days compared with that 
of WT littermates (Figure 1F).
As previously reported, the Col2.3-11bHSD2 transgene is exclu-
sively localized in osteoblasts and osteocytes by immuno histo-
chemical staining (26, 27). To confirm that under the conditions 
of corticosterone treatment, as used in our study, glucocorticoid 
signaling is reduced or absent in the osteoblasts of Tg mice, we 
analyzed the expression of 2 genes known to be induced in WT 
mice by glucocorticoids: glucocorticoid-induced leucine zipper 
(Gilz) (29) and FK506-binding protein 5 (Fkbp5) (30). We observed 
that these genes were induced in the tibias of WT corticoster-
one-treated mice but not in those of the Tg mice treated with glu-
cocorticoids (Figure 2, A and B).
Muscle and liver tissues are considered to be metabolically active 
organs, and the expression of GILZ and FKBP5 in these tissues 
was measured in response to glucocorticoid treatment to confirm 
that glucocorticoid signaling in these organs was not affected in 
Tg mice. We observed no differences in the regulation of Gilz and 
Fkbp5 by glucocorticoid treatment in WT and Tg mice in either 
muscle or liver RNA extracts (Figure 2, C–F). These results indicate 
that the expression of the 11βHSD2 transgene in the osteoblasts 
of Tg mice also does not have any direct impact on the known 
effects of glucocorticoids in muscle and liver.
11βHSD2 was not detected by immunohistochemical staining of 
adipocytes (data not shown). To confirm that glucocorticoid sig-
naling in adipocytes of Tg mice was not affected by the transgene, 
we measured the expression levels of 6 genes known to be regulated 
Figure 2
Targeted disruption of glucocorticoid signal-
ing in osteoblasts affects acute glucocorti-
coid signaling in osteoblasts but not muscle 
or liver as shown by qRT-PCR. (A and B) 
Quantitative RT-PCR analysis of tibia RNA 
expression in WT and Tg mice treated for 
3 days with either placebo or corticoster-
one of genes known to be modulated by 
glucocorticoids: (A) Gilz and (B) Fkbp5. 
(C and D) Quantitative RT-PCR analysis 
of muscle RNA expression of (C) Gilz and 
(D) Fkbp5 in WT and Tg mice treated for 
3 days with placebo or corticosterone. (E 
and F) Quantitative RT-PCR analysis of 
liver RNA expression of (E) Gilz and (F) 
Fkbp5 in WT and Tg mice treated for 3 days 
with placebo or corticosterone. *P < 0.05, 
#P < 0.01, †P < 0.001 compared with respec-
tive genotype placebo-treated controls; 
**P < 0.01 WT 1.5 mg GC compared with Tg 
1.5 mg GC (2-way ANOVA followed by post-
hoc analysis; error bars represent SEM).
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in adipocytes by exogenous glucocorticoids, using qRT-PCR on 
adipose tissue excised from the mice. We found that Gilz, Fkbp5, 
11β-hydroxysteroid dehydrogenase type 1 (Hsd11b1), fatty acid 
binding protein 4 (Fabp4, also known as adipocyte protein 2 or Ap2), 
Pparg, and CCAAT-enhancer-binding protein α (Cebpa) were not 
differently regulated in WT and Tg mice following glucocorticoid 
treatment (Figure 3). These results indicate that the expression of 
the 11βHSD2 transgene in the osteoblasts of Tg mice does not have 
any direct effect on known effects of glucocorticoids in adipocytes.
Disruption of osteoblastic glucocorticoid signaling prevents glucocor-
ticoid-induced insulin resistance and glucose intolerance. Corticoster-
one-induced fat accumulation and hyperlipidemia were signifi-
cantly attenuated in Tg mice, suggesting that osteoblast-specific 
glucocorticoid signaling has a role in mediating the metabolic 
consequences of exogenous glucocorticoids on body composition. 
As the transgene itself had no effect on genetic markers of adipo-
cyte function and differentiation, we hypothesized that our obser-
vations are attributable to changes in fuel metabolism caused by 
the effects of glucocorticoids on osteoblast function. To test this 
hypothesis, we performed both insulin tolerance tests (ITTs) and 
oral glucose tolerance tests (oGTTs) on WT and Tg mice receiv-
ing either 1.5 mg corticosterone per week or placebo. Tests were 
performed at weekly intervals (days 0, 3, 7, 14, 21, and 28) over a 
28-day treatment period.
All animals exhibited a similar response to insulin prior to the 
implantation of corticosterone- or placebo-containing pellets (Fig-
ure 4A). This pattern was also observed on day 3 of the treatment 
(Figure 4B). Placebo-treated WT and placebo-treated Tg mice con-
tinued with this same response over the course of the experiment, 
with a rapid drop in blood glucose following an insulin injection 
and a return toward baseline values within 2 hours (Figure 4, A–F). 
As expected, WT mice treated with corticosterone became insulin 
resistant as early as 7 days into treatment (Figure 4C). It should 
be noted that osteocalcin levels decreased immediately following 
treatment of WT mice with corticosterone (i.e., on day 1) and that 
the change in insulin responsiveness occurred subsequent to the 
decrease in osteocalcin levels (i.e., on day 7). This resistance was 
observed until the end of the experiment on day 28, with blood 
glucose levels remaining unchanged over the 2-hour period follow-
ing an insulin injection (Figure 4, C–F). In contrast, corticoster-
one-treated Tg mice showed a normal response to insulin on day 7 
(Figure 4C; P < 0.001 at t = 60, 90, and 120 minutes), although 
partial insulin resistance became evident from day 14 onward. 
Corticosterone-treated Tg mice, however, continued to exhibit a 
response to insulin that was significantly different from that of cor-
ticosterone-treated WT mice throughout the duration of the exper-
iment. Absolute values are shown in Supplemental Figure 1, A–F.
oGTTs were performed to determine the effect of disrupted 
osteoblastic glucocorticoid signaling on glucose metabolism. A 
bolus dose of 2 g/kg glucose was administered via gavage, and 
blood glucose levels were monitored over 2 hours. At baseline, 
all mice showed a physiological response to glucose (Figure 4G). 
This pattern was also observed on day 3 of the treatment (Figure 
4H) and was maintained in placebo-treated WT and Tg animals 
but also in corticosterone-treated Tg mice throughout the 28-day 
experimental period. In contrast, corticosterone-treated WT litter-
mates were glucose intolerant from day 7 to day 28 (Figure 4, I–L).
Using data from the above metabolic tests, we analyzed the base-
line fasting blood glucose and insulin levels at days 0, 7, 14, 21, and 
28. Fasting glucose levels increased in a time-dependent manner in 
corticosterone-treated WT mice, while no changes in fasting blood 
glucose levels were observed in corticosterone-treated Tg mice or 
Figure 3
Targeted disruption of glucocorti-
coid signaling in osteoblasts does 
not affect acute glucocorticoid sig-
naling in white adipose tissue as 
shown by qRT-PCR. Quantitative 
RT-PCR analysis of white adipose 
tissue RNA expression in WT and 
Tg mice treated for 3 days with 
either placebo or corticosterone of 
genes known to be modulated by 
glucocorticoids: (A) Gilz, (B) Fkbp5, 
(C) Fabp4, (D) Hsd11b1, (E) Pparg, 
and (F) Cebpa. *P < 0.05, #P < 0.01 
compared with respective genotype 
placebo-treated controls (2-way 
ANOVA followed by post-hoc analy-
sis; error bars represent SEM).
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placebo-treated mice (Figure 5A). Surprisingly, however, we found 
that corticosterone treatment was associated with a time-depen-
dent significant increase in serum insulin levels regardless of geno-
type, with no change in the placebo-treated groups (Figure 5B).
Taken together, these data suggest that exogenous glucocorti-
coids, through a suppression of osteoblast activity, impair insulin 
sensitivity and thereby glucose uptake in insulin target tissues.
Serum total and undercarboxylated osteocalcin levels are suppressed in 
WT but not in Tg corticosterone-treated mice. In keeping with clinical 
observations (12, 14), treatment with exogenous glucocorticoids 
resulted in a rapid and significant decrease in serum total osteo-
calcin levels in WT mice (–75% at day 28 compared with baseline; 
Figure 5C). This effect was still present in Tg mice (58% reduction 
by day 28 compared with baseline), although serum total osteocal-
cin levels remained significantly higher than those of corticoster-
one-treated WT mice (Figure 5C). In placebo-treated mice, serum 
osteocalcin levels fell slowly over time, consistent with the normal, 
growth-associated reduction in bone turnover.
Figure 4
Targeted disruption of glucocorticoid signaling in osteoblasts partially prevents impaired metabolic responses seen in glucocorticoid-treated WT 
mice. (A–F) ITTs in WT (red) and Tg (blue) mice treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed lines). (G–L) 
oGTTs on WT (red) and Tg (blue) mice treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed lines). *P < 0.05, 
#P < 0.01, †P < 0.001 compared with respective genotype placebo-treated controls; ‡P < 0.05, **P < 0.01, ##P < 0.001 WT 1.5 mg GC compared 
with Tg 1.5 mg GC (repeated-measures ANOVA followed by post-hoc analysis for time-dependent measurements; error bars represent SEM).
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We also determined the levels of undercarboxylated osteocalcin 
in these same mice. We found that in WT mice corticosterone ther-
apy induced a decrease in both serum total and undercarboxylated 
osteocalcin levels, with no change in the percentage of undercar-
boxylated osteocalcin. In contrast, undercarboxylated osteocalcin 
levels remained unchanged in Tg corticosterone-treated mice at all 
the time points tested (Figure 5D).
Prevention of glucocorticoid-induced metabolic dysfunction  
by osteocalcin gene therapy
It has recently been reported that osteocalcin may be involved in 
the regulation of glucose metabolism (22, 23) by modifying insu-
lin secretion and sensitivity (31) as well as pancreatic β cell pro-
liferation (23). Our own findings in Col2.3-11bHSD2 Tg animals 
led us to reason that the glucocorticoid-induced suppression of 
osteoblast activity may play a central role in mediating the adverse 
effects of glucocorticoids on glucose and lipid metabolism. We 
therefore hypothesized that replacing osteocalcin in the circula-
tion would prevent or at least ameliorate the metabolic changes 
observed in WT animals exposed to exogenous glucocorticoids. 
Furthermore, prior studies have pointed to uncarboxylated 
osteocalcin as the active metabolic regulator (22, 25). We there-
fore developed a method by which the carboxylation status of the 
replaced osteocalcin is controlled. This enabled us to determine 
whether there are any differences between the effects of either car-
boxylated or uncarboxylated osteocalcin on glucose metabolism.
In our hands, purified native or thermally decarboxylated osteo-
calcin administered either via injection or slow-release osmotic 
pumps failed to generate measurable sustained serum osteocal-
cin levels. We were not able to induce any metabolic effects in 
untreated or corticosterone-treated animals using these admin-
istration techniques. To overcome this problem and to generate 
measurable and sustained levels of osteocalcin in the circula-
tion, we used hydrodynamic tail vein injection (hTVI) to trans-
fect hepatocytes in vivo with a plasmid containing osteocalcin 
(OC, also known as Bglap) and a commercially available vector 
(pLIVE, Mirus Bio), which targets expression to the liver via the 
minimal mouse albumin promoter and the mouse α-fetoprotein 
enhancer. This leads to hepatic transgene expression and has been 
reported to enable secretion of transfected proteins into the cir-
culation (32). In order to control for the carboxylation status of 
the transfected osteocalcin, we constructed both a WT full-length 
OC (wtOCN) and a mutant OC (μOCN) plasmid. In the latter, the 
3 γ-carboxylation sites (glutamic acid residues or Glu) are substi-
Figure 5
Targeted disruption of glucocorticoid signaling in osteoblasts partially prevents impaired metabolic responses seen in glucocorticoid-treated WT 
mice but has no effect on total serum insulin concentrations. (A) Baseline fasting blood glucose concentration levels in WT and Tg mice treated 
with 1.5 mg corticosterone per week or placebo over the 4-week period (day 0, before treatment; day 28, after 4 weeks of treatment). (B) Baseline 
fasting serum insulin levels in WT and Tg mice treated with 1.5 mg corticosterone per week or placebo over the 4-week period. conc, concen-
tration. (C) Serum total osteocalcin concentrations in WT and Tg mice treated with 1.5 mg corticosterone per week or placebo over the 4-week 
period (composite of 2 experiments standardized by expression as percentage of baseline). (D) Serum uncarboxylated osteocalcin (unOCN) 
concentrations in WT and Tg mice treated with 1.5 mg corticosterone per week or placebo over the 4-week period (composite of 2 experiments 
standardized by expression as percentage of baseline). *P < 0.05, #P < 0.01, †P < 0.001 compared with respective genotype placebo-treated 
controls; ‡P < 0.05, ##P < 0.001 WT 1.5 mg GC compared with Tg 1.5 mg GC (repeated-measures ANOVA followed by post-hoc analysis for 
time-dependent measurements; error bars represent SEM).
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tuted with aspartic acid residues (Asp), leading to the expression 
of an osteocalcin protein that is unable to undergo carboxylation. 
This method of controlling the carboxylation status of osteo calcin 
has been previously used to inactivate vitamin K–dependent clot-
ting factors (33). Furthermore, for validation purposes (see below), 
we cloned green fluorescent protein (gfp) into the pLIVE vector. In 
all experiments, an empty vector (EV) was used as a control.
First, transfection via hTVI was validated using the gfp-contain-
ing plasmid. Analysis of frozen liver sections confirmed GFP pro-
tein expression by hepatocytes at 7, 14, 21, and 28 days after trans-
fection (Figure 6A). Qualitative (end-point) PCR on RNA extracted 
from whole livers corroborated hepatic osteocalcin (OC) expres-
sion in mice receiving the wtOCN or μOCN construct via hTVI 
(Figure 6B). We further quantified hepatocytic GFP expression 
by isolating hepatocytes from mice receiving the GFP construct 
via hTVI. GFP was expressed by 5.5% ± 0.3% of viable hepatocytes 
7 days after the transfection (Figure 6C). This is in keeping with 
results of other in vivo transfections (32).
We then determined whether osteocalcin gene therapy would 
prevent, or at least ameliorate, the effects of glucocorticoids on 
Figure 6
Validating heterotopic expression following gene therapy using hTVI. (A) Fluorescent GFP expression in frozen liver sections 7, 14, 21, and 28 
days after hTVI of the pLIVE vector containing GFP. Halogen light microscope images of same fields of view appear in the bottom row. Original 
magnification, ×100. (B) RT-PCR of RNA extracted from liver segments of mice 28 days after hTVI of vectors containing either no cDNA insert 
(EV) or the wtOCN or the μOCN insert to determine RNA expression of osteocalcin (OC). 18S was amplified as the housekeeping gene for load-
ing reference. RNA was also extracted from mouse tibias as a positive control for OC expression. (C) Fluorescent image of GFP expression in 
primary hepatocytes isolated from mice 28 days after hTVI of pLIVE vector plus GFP cDNA. A halogen light microscope image of the same field 
of view appears in the bottom row. Original magnification, ×200. (D) Serum osteocalcin concentrations (measured by IRMA) of EV, wtOCN, and 
μOCN vector–receiving mice treated with 1.5 mg corticosterone per week or placebo (plc) over the 4-week period.
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glucose metabolism. To this aim, 7-week-old WT mice were treated 
with 1.5 mg corticosterone per week, or placebo, for 28 days 
(n = 60), starting on day 0. On day 8, animals received EV (n = 20), 
wtOCN vector (n = 20), or μOCN vector (n = 20) via hTVI, resulting 
in the allocation of 10 mice per group of either placebo or gluco-
corticoid treatment for each of the 3 vectors (Figure 6D).
Baseline osteocalcin levels varied between 70 and 75 ng/ml. 
During the first 7 days of this experiment, serum osteocalcin 
levels remained unchanged in placebo-treated mice, whereas 
mice treated with corticosterone displayed a marked and rapid 
drop to approximately 40% of baseline at day 7 (39.3 ± 2.0 ng/ml, 
37.3 ± 2.3 ng/ml, and 35.6 ± 2.7 ng/ml in corticosterone-treated 
EV-, wtOCN-, and μOCN-receiving mice, respectively; Figure 6D). 
Delivery of osteocalcin-containing vectors resulted in an increase 
in serum osteocalcin concentrations corticosterone-treated 
groups (55.4 ± 8.4 ng/ml and 56.4 ± 3.9 ng/ml; Figure 6D). Osteo-
calcin levels in mice receiving the EV and corticosterone contin-
ued to decrease, with levels reaching 17% of their initial baseline 
concentrations (19.3 ± 3.8 ng/ml).
Effect of osteocalcin gene therapy on body weight, composition, and hyper-
lipidemia in corticosterone-treated mice. Total body weight gradually 
increased in all groups, as expected for young adult mice. In mice 
receiving corticosterone and the EV, total body weight at end point 
was significantly higher than that in all other groups, including 
mice receiving corticosterone and the functional osteocalcin vec-
tors (P < 0.05; Figure 7A). In regards to body composition, lean 
mass was always somewhat lower in the corticosterone-treated 
mice compared with that in placebo-treated controls receiving 
the same vector. This was most pronounced in the EV groups, 
in which the difference was significant as early as day 14 (Figure 
7B). Fat mass was markedly increased in EV mice receiving cor-
ticosterone, consistent with the increase in total body weight in 
this group. Corticosterone-treated animals receiving the either 
the μOCN or the wtOCN vector displayed a smaller increase in 
Figure 7
Heterotopic expression of osteocalcin from day 8 reduces glucocorticoid-induced changes in body composition. (A) Body weight as percentage 
of baseline of EV, wtOCN, and μOCN vector–receiving mice (vector administered via hTVI on day 8) treated with 1.5 mg corticosterone per 
week or placebo over the 4-week period. (B) Lean body mass of vector-receiving mice treated over the 4-week period. (C) Body fat mass of 
vector-receiving mice treated over the 4-week period. (D) Fat/lean mass ratio of vector-receiving mice treated over the 4-week period. (E) Serum 
triglyceride levels of vector-receiving mice treated over the 4-week period. (F) Serum cholesterol levels of vector-receiving mice treated over the 
4-week period (“for all” indicates that significance applies to all groups at this time point). *P < 0.05, #P < 0.01, †P < 0.001 compared with respective 
vector-receiving placebo-treated controls; ‡P < 0.05, **P < 0.01 compared with other corticosterone-treated groups receiving wtOCN and μOCN 
vectors (repeated-measures ANOVA followed by post-hoc analysis; error bars represent SEM).
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body fat mass over time, although total fat mass was significantly 
higher than that in the respective placebo-treated controls at day 
21 and day 28. In the placebo-treated groups, EV mice displayed a 
slight increase in fat mass, which may be due to normal fat accrual 
associated with ageing, while the placebo-treated wtOCN and 
μOCN mice gained no fat mass over the 4-week period and were 
not significantly different from each other (Figure 7C).
When changes in body composition were expressed as a ratio 
of fat to lean body mass, we found that mice receiving corticos-
terone and the EV developed a significantly higher fat/lean mass 
ratio compared with both their own baseline and corticoster-
one-treated wtOCN and μOCN vector-receiving mice. While cor-
ticosterone-treated mice harboring either of the osteocalcin vec-
tors acquired significantly greater fat/lean mass ratios compared 
with those of respective placebo-treated controls, these mice never 
reached significantly greater fat/lean mass ratios than their base-
line values (Figure 7D). These changes in fat/lean mass in the 
EV-receiving corticosterone-treated mice suggests there is a redis-
tribution of energy from muscle to fat.
Serum triglyceride levels at day 7 were significantly higher in all 
corticosterone-treated mice compared those in placebo-treated 
controls (Figure 7E). Following the introduction of the vectors 
at day 8, serum triglyceride levels remained significantly higher 
in mice receiving the EV, yet fell to levels comparable to those 
observed in placebo-treated controls in animals receiving either the 
wtOCN or the μOCN vector. This effect was visible by day 14 and 
remained for the duration of the experiment (Figure 7E). Serum 
cholesterol levels increased slightly in all corticosterone-treated 
mice by day 7 (Figure 7F). Cholesterol levels remained higher in 
EV-receiving corticosterone-treated mice than in placebo-treated 
mice, and this difference was significant by day 28. Cholesterol 
levels fell and remained comparable to those of placebo-treated 
controls in wtOCN and μOCN vector–receiving mice following the 
introduction of these vectors (after day 8; Figure 7F).
Glucose metabolism — osteocalcin gene therapy reverses the metabolic 
effects of glucocorticoid treatment. In order to determine whether 
osteocalcin plays a role in glucocorticoid-induced insulin resis-
tance, we performed ITTs in vector-receiving, corticosterone- or 
placebo-treated mice at days 0, 7, 14, 21, and 28. A secondary aim 
was to establish whether carboxylated and uncarboxylated osteo-
calcin would have different effects on insulin sensitivity in gluco-
corticoid-treated animals. At baseline (day 0), all mice displayed 
similar insulin sensitivities (Figure 8A and Figure 9A).
All placebo-treated mice continued to display an ITT response 
that was similar to their baseline response at all time points tested. 
Mice treated with corticosterone became insulin resistant as early 
as 7 days after onset of corticosterone treatment (Figure 8B and 
Figure 9B). For corticosterone-treated mice harboring the EV, 
this resistance was observed until end point (day 28) (Figure 8, 
B–E, and Figure 9, B–E). In contrast, corticosterone-receiving mice 
transfected with the wtOCN vector regained a partial sensitivity 
to insulin by day 28 and were significantly different from the glu-
cocorticoid-treated EV-receiving group at the 30- and 60-minute 
time points (Figure 8E). Mice that received the μOCN vector and 
were treated with glucocorticoids also demonstrated partial pro-
tection from insulin resistance, although in this case changes were 
Figure 8
Heterotopic expression of wtOCN improves glucocorticoid-induced insulin resistance. ITTs in EV- (red) and wtOCN (black) vector–receiving mice 
(vector administered via hTVI on day 8) treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed lines) on (A) day 0, 
(B) day 7, (C) day 14, (D) day 21, and (E) day 28. *P < 0.05, #P < 0.01, †P < 0.001 compared with respective vector-receiving placebo-treated 
controls; ‡P < 0.05 compared with other corticosterone-treated groups receiving μOCN or wtOCN vectors (repeated-measures ANOVA followed 
by post-hoc analysis for time-dependent measurements; error bars represent SEM).
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noted from day 14 (Figure 9, B–E). Absolute values are shown in 
Supplemental Figure 2, A–J.
In order to test for changes in glucose handling, we performed 
oGTTs at day 0 and again at days 7, 14, 21, and 28. At day 0, all 
groups responded similarly to an orally administered bolus of glu-
cose (2 g/kg body weight; Figure 10A and Figure 11A). At day 7, pla-
cebo-treated mice had the same response to glucose that they did at 
baseline, while mice treated with corticosterone had become glucose 
intolerant (Figure 10B and Figure 11B). Mice receiving corticoster-
one and the EV remained intolerant to glucose for the remaining 
time points measured, days 14, 21, and 28 (Figure 10, C–E, and Fig-
ure 11, C–E). In contrast, corticosterone-treated mice receiving the 
wtOCN or the μOCN vectors regained physiological glucose toler-
ance from day 14 to day 28 (Figure 10, C–E, and Figure 11, C–E), indi-
cating that the presence of osteocalcin, in both the carboxylated and 
uncarboxylated forms, enables the mice to handle glucose normally.
Using data from the above metabolic tests, we calculated the base-
line fasting blood glucose and insulin levels for mice from each of 
the 6 groups. We again found that corticosterone treatment of mice 
harboring the EV was associated with a significant and time-depen-
dent increase in fasting blood glucose levels (Figure 11F). In con-
trast, corticosterone-treated mice transfected with the μOCN con-
struct had fasting blood glucose concentrations indistinguishable 
from those of placebo-treated mice. Corticosterone-treated animals 
harboring the wtOCN vector showed a similar picture, except that 
at end point (day 28) blood glucose levels were significantly higher 
than those in placebo-treated controls (Figure 11F).
Treatment with cortico sterone substantially and time-depen-
dently increased serum insulin levels, regardless of whether the 
mice had received an empty or OCN-containing vector (Figure 
11G). All placebo groups remained unchanged over time regard-
less of the vector they received.
Lipid deposition in the liver — osteocalcin gene therapy prevents gluco-
corticoid-induced increased lipid deposition. It is well documented that 
long-term glucocorticoid therapy leads to liver steatosis or fatty 
liver (34). Based on our findings thus far, we hypothesized that this 
effect may be associated with the downregulation of osteocalcin. 
To test this hypothesis, we analyzed lipid deposition in the livers 
of our experimental mice by Oil Red O staining on frozen liver sec-
tions. With an average 21.2% ± 1.85% of total measured area being 
positive for lipid deposition, placebo-treated EV-receiving mice had 
little steatosis, although lipid could be identified in the area sur-
rounding the central veins, in which hypoxia may have been pres-
ent. Lipid deposition was significantly increased in EV-receiving 
mice treated with corticosterone, with average Oil Red O–stained 
areas rising to 46.23% ± 2.66% of total measured areas (P < 0.001; 
Figure 12, A and B). Sections analyzed from placebo-treated mice 
receiving the wtOCN and μOCN vectors were found to have 
almost no lipid content, with Oil Red O staining seen in only 
0.12% ± 0.01% and 1.15% ± 0.17% of total measured areas, respec-
tively. Corticosterone-treated wtOCN- and μOCN-receiving mice 
also had very little hepatic lipid accumulation, with staining cov-
ering only 1.10% ± 0.06% and 12.41% ± 0.92% of total measured 
areas, respectively (Figure 12, A and B). While our preliminary 
Figure 9
Heterotopic expression of μOCN improves glucocorticoid-induced insulin resistance. ITTs in EV- (red) and μOCN (blue) vector–receiving mice 
(vector administered via hTVI on day 8) treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed lines) on (A) day 0, (B) 
day 7, (C) day 14, (D) day 21, and (E) day 28. *P < 0.05, #P < 0.01, †P < 0.001 compared with respective vector-receiving placebo-treated controls; 
‡P < 0.05 compared with other CS, corticosterone-treated groups receiving μOCN or wtOCN vectors (repeated-measures ANOVA followed by 
post-hoc analysis for time-dependent measurements; error bars represent SEM).
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studies could find no effect on metabolic parameters when osteo-
calcin was directly placed into the circulation, gene therapy that 
produced local pharmacologic doses of the protein were effective. 
Collectively, our results suggest that the effects of osteocalcin on 
insulin function predominantly occur in the insulin target organs, 
such as the liver and muscle. This led us to hypothesize that there 
were changes also to the insulin signaling pathway in hepatocytes, 
which is intrinsically involved in liver glucose metabolism.
Insulin signaling in target tissues is protected in mice receiving functional 
osteocalcin vectors. We therefore performed Western blots using 
protein extracted from isolated hepatocytes to determine whether 
insulin signaling was changed in the liver. Isolated hepatocytes 
were treated for 24 hours with 100 mM corticosterone or vehicle 
before cells were lysed. We found that the insulin receptor (InsR) 
was not regulated by either of the vectors or by corticosterone 
treatment (Figure 12C). In a second experiment, in addition to the 
above conditions, we also treated the cells with 50 nM insulin or 
placebo for 5 minutes before cells were lysed. These conditions are 
known to trigger phosphorylation of the InsR in hepatocytes (35). 
No phosphorylated InsR was detected in hepatocytes from EV-re-
ceiving mice that were not treated with insulin prior to lysis. Stim-
ulating the hepatocyte cultures with insulin for 5 minutes prior 
to lysis lead to the phosphorylation of the InsR as observed by 
Western blotting, and this insulin-induced phosphorylation was 
markedly reduced in EV hepatocytes exposed to corticosterone for 
24 hours (lane 4, Figure 12D). Such inhibition of InsR phospho-
rylation induced by corticosterone was prevented in hepatocytes 
from mice that received either the wtOCN or μOCN vectors.
Discussion
Our studies demonstrate, for the first time to our knowledge, that 
the skeleton and specifically the osteoblast play a central role in 
the pathogenesis of the detrimental effects of exogenous high-
dose glucocorticoids on systemic fuel metabolism (Figure 13). 
Recent reports have posited both the osteoblast and the osteoclast 
as major determinants in the physiological control of murine 
energy metabolism (22, 25, 31, 36). Our findings now provide a 
basis for a deeper understanding of the pathophysiology of gluco-
corticoid-induced diabetes and related metabolic disorders, con-
ditions that are of clinical relevance to a wide range of patients.
Glucocorticoid-induced changes in fuel metabolism are mediated by the 
skeleton. The enzyme 11bHSD2 inactivates corticosterone, the 
active glucocorticoid in mice, at the prereceptor level. In Col2.3-
11bHSD2 Tg mice, targeted overexpression of this enzyme results 
in a disruption of normal glucocorticoid signaling exclusively in 
mature osteoblasts and osteocytes (26). We have recently shown 
that the skeleton of Col2.3-11bHSD2 Tg mice is protected from 
the adverse effects of long-term glucocorticoid treatment (10). 
We now demonstrate that disruption of glucocorticoid signaling 
in the same cells also prevents, or even reverses, the deleterious 
effects of exogenous high-dose glucocorticoids on whole-body fuel 
metabolism. Compared with WT mice, body weight and fat mass 
Figure 10
Heterotopic expression of wtOCN improves glucocorticoid-induced glucose tolerance. oGTTs in EV- (red) and wtOCN (black) vector–receiving 
mice (vector administered via hTVI on day 8) treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed lines) on (A) day 0, 
(B) day 7, (C) day 14, (D) day 21, and (E) day 28. *P < 0.05, #P < 0.01, †P < 0.001 compared with respective vector-receiving placebo-treated 
controls; ‡P < 0.05, **P < 0.01, ##P < 0.001 compared with other CS, corticosterone-treated groups receiving μOCN or wtOCN vectors (repeated- 
measures ANOVA followed by post-hoc analysis for time-dependent measurements; error bars represent SEM).
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accrual, increased adipose cell size, insulin resistance, and glucose 
intolerance were significantly less pronounced or even absent in 
corticosterone-treated Col2.3-11bHSD2 Tg mice. These findings 
clearly indicate that a factor, or several factors, originating from 
osteoblasts and modified by glucocorticoid signaling in these very 
cells is responsible for the adverse effects of glucocorticoids on sys-
temic energy metabolism and body composition. The expression 
of the 11bHSD2 transgene in the osteoblasts of Tg mice does not 
have any direct effect on the actions of glucocorticoids in adipo-
cytes, as expression levels of genes known to be regulated in adi-
pocytes by exogenous glucocorticoids remained intact. 11bHSD1, 
an enzyme that converts inactive glucocorticoids to their active 
metabolites (37), is known to be rapidly upregulated by its sub-
strate (38). Similarly, Fabp4, a member of the fatty acid binding 
protein family known to be involved in adipocyte differentiation 
and fatty acid uptake, has been shown to be upregulated by exoge-
nous glucocorticoid treatment (39). PPARγ and CEBPα have been 
positively correlated with glucocorti coid binding of the GR (40). 
Glucocorticoid treatment did not differentially regulate Gilz, 
Fkbp5, Hsd11b1, Fabp4, Pparg, and Cebpa in WT and Tg mice.
Importantly, prereceptor inactivation of corticosterone in osteo-
blasts also significantly attenuated the otherwise pronounced 
suppression of osteocalcin synthesis and secretion regularly 
seen following exogenous glucocorticoid administration. Thus, 
Figure 11
Heterotopic expression of μOCN from day 8 improves glucocorticoid-induced glucose tolerance. (A–E) oGTTs in EV- (red) and μOCN (blue) 
vector–receiving mice (vector administered via hTVI on day 8) treated with either placebo (solid lines) or 1.5 mg corticosterone per week (dashed 
lines) on (A) day 0, (B) day 7, (C) day 14, (D) day 21, and (E) day 28. (F) Baseline fasting blood glucose concentration levels in EV- and wtOCN 
and μOCN vector–receiving mice treated with 1.5 mg corticosterone per week or placebo over the 4-week period. (G) Fasting serum insulin 
levels in EV- and wtOCN and μOCN vector–receiving mice treated with 1.5 mg corticosterone per week or placebo over the 4-week period (“for 
all” indicates that significance applies to all groups at this time point). *P < 0.05, #P < 0.01, †P < 0.001 compared with respective vector-receiving 
placebo-treated controls; ‡P < 0.05, **P < 0.01, ##P < 0.001 compared with other CS, corticosterone-treated groups receiving μOCN or wtOCN 
vectors (repeated-measures ANOVA followed by post-hoc analysis for time-dependent measurements; error bars represent SEM).
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a significant and sustained increase in serum osteocalcin levels 
despite treatment with corticosterone. In contrast, osteo calcin 
concentrations remained suppressed in glucocorticoid-treated 
mice carrying the EV. While the latter mice gained significantly in 
body weight and fat mass in response to corticosterone treatment, 
these effects were absent in similarly treated but osteocalcin-re-
plete littermates, indicating that mice transfected with the func-
tional osteocalcin vector were able to maintain normal body com-
position despite glucocorticoid treatment. Indeed, mice receiving 
both the EV and corticosterone had the lowest lean body mass 
and the highest percentage of body fat mass of all the groups. The 
resulting rise in fat/lean mass ratio indicates that corticosterone 
treatment induces a redistribution of “energy” from muscle to fat.
When the total body fat/lean mass ratio was calculated for 
mice receiving the functional osteocalcin vectors, no increase was 
observed compared with baseline ratios. There was, however, a sig-
nificant increase from day 21 when compared with their respective 
placebo-treated control groups. This latter point is not surprising 
as OCN vector-receiving placebo-treated groups had a decrease in 
their total body fat/lean mass ratio over the 4-week period. This 
indicates that the presence of osteocalcin itself, expressed het-
erotopically in the liver, leads to an overall decrease in fat mass, 
regardless of glucocorticoid treatment. We are yet to uncover the 
mechanism behind this effect of osteocalcin on body fat in mice; 
however, this finding does highlight the potential importance of 
serum osteocalcin levels were significantly higher in Tg corticos-
terone-treated mice compared with those in treated WT litter-
mates, in which osteocalcin levels were markedly reduced. The 
latter observation closely mimics the reduction in bone formation 
markers invariably seen in patients treated with even low-dose 
glucocorticoids (12, 14). As previous studies suggested that osteo-
calcin is involved in normal energy metabolism (22, 25, 31, 36), 
we sought to further investigate the role of osteocalcin in gluco-
corticoid-induced dysmetabolism. The possibility that changes 
in osteocalcin levels are indirectly mediated through the effects 
of glucocorticoids on osteoclasts has been investigated in a pre-
vious study (10). We found that serum levels of the bone resorp-
tion marker TRAP5b were increased in glucocorticoid-treated WT 
animals only. Levels of serum TRAP5b in glucocorticoid-treated 
Tg mice remained unchanged, as did levels in both WT and Tg 
placebo-treated groups. These data indicate that changes in serum 
osteocalcin levels in glucocorticoid-treated Tg mice are unlikely 
due to the indirect effects of glucocorticoids on osteoclasts. To test 
whether osteocalcin functions to antagonize the adverse effects of 
corticosterone on fuel metabolism, it was pivotal to generate and 
then sustain measurable levels of osteocalcin in the circulation. To 
this aim, we used the hTVI method of gene therapy and success-
fully delivered plasmids that contained either no additional insert 
(EV), the gfp sequences, or the OC or mutant OC cDNA. Hepatic 
expression of both the wtOCN and μOCN plasmids resulted in 
Figure 12
Heterotopic expression of osteocalcin reduces lipid deposition in the liver and rescues insulin signaling. (A) Oil Red O staining on frozen liver 
sections of EV- and wtOCN and μOCN vector–receiving mice treated with 1.5 mg corticosterone per week or placebo. Original magnification, 
×200. CS, corticosterone. (B) Quantification of Oil Red O in frozen liver sections. Bars represent the percentage of lipid-stained area over total 
measured area. (C) Western blot of total InsR of cell lysate collected from isolated primary hepatocytes of EV- and wtOCN and μOCN vector–
receiving mice. Cells were treated for 24 hours with either corticosterone (100 mM) or placebo. Density ratios were calculated using Quantity 
One software. (D) Western blot of phosphorylated InsR (p-InsR) of cell lysate collected from isolated primary hepatocytes of EV- and wtOCN and 
μOCN vector–receiving mice. Cells were treated for 24 hours with either corticosterone (100 mM) or placebo and stimulated with insulin (50 nM) 
or placebo 5 minutes before lysis. †P < 0.001 compared with respective vector-receiving placebo-treated controls, ##P < 0.001 compared with other 
corticosterone-treated groups receiving μOCN vectors (2-way ANOVA followed by post-hoc analysis; error bars represent SEM).
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lin sensitivity at the target tissue level, allowing normal or near 
normal glucose handling.
We made very similar observations following osteocalcin gene 
therapy, during which corticosterone-treated mice showed a 
marked and time-dependent increase in serum insulin levels, 
regardless of which vector they had received. Thus, insulin levels 
increased in response to corticosterone treatment despite osteo-
calcin being replaced. The difference between osteocalcin-depleted 
and osteocalcin-replete mice was solely seen in blood glucose han-
dling, which was abnormal in the former group and normal in 
latter group. Furthermore, placebo-treated mice receiving either 
of the 2 active osteocalcin vectors displayed fasting serum insulin 
levels that remained unchanged compared with both their own 
baseline (day 0) and the levels seen in placebo-treated EV mice. 
This supports the notion that neither total nor uncarboxylated 
osteocalcin lead to increased serum insulin levels. However, the 
current data suggest that osteocalcin replacement results in 
improved peripheral insulin sensitivity, where the lack of hyper-
glycemia denotes a state of compensated insulin resistance.
Recent studies from both the Karsenty and the Clemens labora-
tories have shown that osteocalcin plays an important if not central 
role in normal glucose metabolism via its effects on both insulin 
production by the pancreatic β cells and insulin sensitivity at the 
target tissues (22, 23, 31). Our data support the hypothesis that 
osteocalcin has an effect on insulin sensitivity at the target tissues. 
It must be noted, however, that we cannot fully conclude that the 
liver is the target organ for circulating osteocalcin, as the liver itself 
was targeted for the expression of osteocalcin in our studies. The 
results of our metabolic tests indicate that replacing osteocalcin in 
glucocorticoid-treated animals leads to an improvement in both 
insulin sensitivity and glucose tolerance. In addition, fat mass in 
our mice is inversely correlated with serum osteocalcin levels, sup-
porting data reported by Ferron and colleagues (22, 23). We did not, 
however, see a difference in regards to the effects of osteocalcin on 
pancreatic insulin secretion. Thus, in our model, we did not observe 
direct effects of osteocalcin on adipose tissue. Not only did osteo-
calcin expression in the liver lead to a decrease in the total fat mass, 
but it also, in both the mutant and WT forms, resulted in a reduc-
tion in corticosterone-induced hypertriglyceridemia and, albeit to 
a lesser degree, hypercholesterolemia. These results indicate that 
osteocalcin may interact with pathway(s) by which glucocorticoids 
increase circulating lipid levels. This phenomenon is also seen in 
patients with metabolic syndrome, in which large increases of corti-
sol are detected alongside significant increases in serum triglyceride 
and cholesterol levels (41, 42). Recent reports also suggest that low 
serum osteocalcin levels are often found in patients with metabolic 
syndrome (43), correlating with high serum triglycerides (44).
Glucocorticoid-induced suppression of osteocalcin modulates the sensitiv-
ity of target tissues to insulin without changes to insulin production per se. 
Based on the results of our ITTs and oGTTs and previous reports 
indicating that osteocalcin stimulates β cell proliferation and 
insulin secretion under physio logical conditions (22, 23, 25), we 
expected that glucocorticoid treatment through the suppression 
of osteocalcin activity would decrease serum insulin levels, result-
ing in hypoinsulinemia in our mice. We also expected that this 
effect would be less pronounced in Tg animals, thereby explaining 
the observed effects on metabolic function and body composition. 
In fact, we observed the exact opposite: corticosterone-treated mice 
exhibited a marked, time-dependent increase in serum insulin lev-
els, regardless of genotype. However, while corticosterone-treated 
WT mice developed severe hyperglycemia, their identically treated 
Tg littermates had normal fasting blood glucose levels, which 
remained unchanged over the experimental period. These results 
indicate that WT mice became insulin resistant in response to glu-
cocorticoid treatment, as is the case in humans. In contrast, mice 
with osteoblast-specific disruption of glucocorticoid signaling 
developed hyperinsulinemia but stayed normoglycemic through-
out the experimental period. We interpret these results to mean 
that WT mice developed complete insulin resistance, while their 
Tg littermates exhibited a pattern consistent with improved insu-
Figure 13
Schematic model of the effects exoge-
nous high-dose glucocorticoids on 
insulin sensitivity and glucose han-
dling in mice. Under physiological con-
ditions, osteocalcin improves insulin 
sensitivity in peripheral tissues such 
as the liver, allowing for efficient glu-
cose handling in times of high insulin 
release. This action is impaired when 
glucocorticoids (GCs) interfere with 
osteoblast activity, suppressing the 
production and secretion of osteocal-
cin (and possibly other factors). The 
lack of osteocalcin leads to decreased 
insulin sensitivity, which results in 
impaired hepatic glucose output inhi-
bition, peripheral glucose uptake, 
hyperglycemia, and a compensatory 
increase in insulin release, all of which 
are characteristic features of glucocor-
ticoid-induced (pre-) diabetes. In the 
absence of osteocalcin, high insulin 
levels have reduced effects on end-or-
gan glucose uptake.
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play major and nonredundant roles in glucose homeostasis and 
InsR regulation in insulin-sensitive organs, such as the liver and 
muscle. These are protein tyrosine phosphatase 1B (PTP1B) and 
T cell protein tyrosine phosphatase (TCPTP) (35, 49). It is possible 
that desensitization of the InsR in glucocorticoid-treated mice is 
PTP dependent. Further work on this signaling pathway is neces-
sary to uncover the mechanism behind this effect.
The reduction in InsR phosphorylation was absent in wtOCN 
and μOCN vector–containing hepatocytes treated with corticoster-
one. Our findings demonstrate a marked negative effect on insulin 
signaling in hepatocytes by glucocorticoids and a positive interfer-
ence in this setting by osteocalcin. It is clear that further studies 
into the interference of insulin signaling by corticosterone, osteo-
calcin, and lipid presence are necessary (50). Furthermore, down-
stream signaling molecules need to be analyzed in this setting, 
including phosphorylation of insulin receptor substrates 1 and 2 
(IRS-1 and IRS-2) and Akt (35) as well as AS160 and Foxo1 (51).
One obvious finding from this study is that there are no major 
differences between the mutant and WT osteocalcin vectors. Both 
active osteocalcin vectors do result in similar effects on target tissue 
insulin sensitivity. The role of this osteoblast-specific protein seems 
to lie outside of the bone microenvironment, and this study is con-
sistent with the involvement of osteocalcin as a mediator of insulin 
sensitivity. When treated with corticosterone, WT mice displayed a 
decrease in the level of both total and undercarboxylated osteocalcin 
but no change in the proportion of undercarboxylated osteocalcin. 
This mimics observations in humans treated with glucocorticoids 
(52). It has also been reported that both the vitamin K–depen-
dent carboxylase activity and the biosynthesis of its substrates are 
enhanced by glucocorticoids (53, 54). This was not seen in Tg mice, 
in which glucocorticoid signaling was disrupted in osteoblasts.
In summary, based on our results, we propose that the skele-
ton, via the osteoblast-osteocyte lineage, plays a pivotal role in the 
pathogenesis of the severe metabolic changes seen in mice chron-
ically treated with pharmacologic doses of glucocorticoids. Thus, 
when glucocorticoid signaling is rendered dysfunctional in mature 
osteoblasts, the effects of exogenously applied glucocorticoids on 
both osteoblast function (e.g., osteocalcin synthesis) and whole-
body fuel metabolism (i.e., insulin sensitivity, glucose handling, 
weight gain) are either completely absent or greatly attenuated. 
Based on our observations in Col2.3-11bHSD2 Tg mice and sup-
ported by the nearly identical results following gene therapy for 
heterotopic osteocalcin expression, it is likely that osteocalcin 
plays a central role in mediating the effects of exogenous gluco-
corticoids on systemic fuel metabolism. Of note, however, hetero-
topic expression of osteocalcin resulted not only in improvements 
of whole-body energy metabolism but also in a reduction of local 
(i.e., hepatic) lipid deposition and improved phosphorylation of the 
InsR expressed by liver cells. Depending on the pathophysiological 
context, osteocalcin may therefore have pleiotropic effects involv-
ing actions on lipid deposition, insulin sensitivity, and/or insulin 
signaling within local target tissues. While we cannot exclude that 
factors other than osteocalcin may be involved in the regulation of 
systemic fuel metabolism, our observations provide clear evidence 
that the deleterious effects of exogenous glucocorticoids on glucose 
and lipid handling are mediated, at least in part, by the skeleton.
Methods
Animals. All mice were from a CD-1 background. Col2.3-11bHSD2 mice, in 
which a truncated 2.3-kb fragment of the proximal promoter and most of 
a rise in serum insulin levels in response to the hepatic expression 
of osteocalcin. This disparity is likely due to differences in the var-
ious mouse models investigated. While the previous studies have 
used models of physiology and obesity (22, 23, 31), our approach 
focuses on the pathophysiology of glucocorticoid-induced dysme-
tabolism. Therefore, some of the differences we observed in com-
parison to previous reports are likely due to the effects of glucocor-
ticoids on tissues other than the skeleton. One of these effects may 
play a role in the increases we observed in fasting serum insulin lev-
els in all animals treated with corticosterone, regardless of genotype 
or osteocalcin replacement. There is evidence that glucocorticoids 
may upregulate preproinsulin in pancreatic islet cells (45) and act 
as weak stimulators of insulin release (46, 47). Some of our results, 
indeed, seem to suggest that corticosterone, given at the dose used 
in this study, is able to stimulate an increase in insulin release in 
these mice. However, while direct effects of corticosterone on pan-
creatic islet cells cannot be excluded at this point, our data suggest 
that the changes in insulin levels seen in our animals are largely 
driven by peripheral insulin resistance.
Taken together, our results provide evidence that osteocalcin 
plays a significant role in the sensitivity of insulin target tissues 
and therefore in the maintenance of whole-body energy metabo-
lism (Figure 13). Our findings further suggest that within the set-
ting of glucocorticoid excess, the metabolic effects of long-term 
glucocorticoid treatment result from the suppression of osteo-
calcin synthesis and release by the osteoblast. These changes pre-
cede the changes in glucose handling and insulin responsiveness, 
which are not detected until a week after corticosterone treatment 
has been established.
Liver responses to overexpression of osteocalcin. The current data 
indicate that a marked decrease in serum osteocalcin levels, as 
is observed following glucocorticoid therapy, correlates with 
decreased sensitivity of the target tissues to insulin. As the effects 
of osteocalcin in our mice did not appear to be at the pancreatic 
level, we decided to study the action of corticosterone on insulin 
target tissues, in particular the liver.
We found that hepatic expression of osteocalcin-containing vec-
tors prevented glucocorticoid-induced hepatosteatosis. Even the 
limited lipid storage observed in 12-week-old control mice receiv-
ing the EV was almost completely absent in osteocalcin vector–
receiving mice. The exact mechanism behind the effect of osteocal-
cin on lipid deposition or perhaps lipolysis in hepatocytes remains 
unclear. It is possible that the hyperinsulinemia induced by excess 
glucocorticoids drives lipogenesis via increased expression of the 
key transcription factor SREBP-1c or that glucocorticoids directly 
stimulate lipogenic pathways in liver by altering gene expression 
(48). It is possible, therefore, that these pathways are activated by 
glucocorticoids and directly inhibited by osteocalcin. Whether sim-
ilar effects are present in other metabolically active insulin-sensitive 
organs, such as muscle and adipose tissue, needs to be investigated.
However, we do provide evidence that osteocalcin plays a role 
in insulin signaling at the target tissue level. In further experi-
ments, we have therefore focused on insulin signaling pathways in 
hepatocytes. We found that neither glucocorticoids nor osteocalcin 
affect the total expression of the InsR, rather a desensitization of 
the receptor occurs with glucocorticoid treatment, which is pro-
tected in the presence of osteocalcin. This desensitization may be a 
consequence of the effect of glucocorticoids on one of those mol-
ecules responsible for InsR dephosphorylation. A large amount of 
recent work has demonstrated that 2 protein tyrosine phosphatases 
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expression vector to generate the construct of wtOCN 
and μOCN, respectively. Green fluorescent protein 
(gfp) was also constructed into the pLIVE vector as one 
of the control vectors (GFP).
pLIVE EV, GFP, or wtOCN and μOCN DNA con-
structs (50 μg/10% volume mouse body weight) were 
hydrodynamically delivered to mice for expression in 
the liver. Preparation of DNA for in vivo delivery was 
performed under sterile conditions as follows: 50 μg of 
DNA plasmid was diluted into 10% volume mouse body 
weight of endotoxin-free and sterile Trans IT delivery 
solution (Mirus). The total injection volume was deter-
mined using the following formula: total volume per 
mouse (ml) = (mouse body weight [g]/10) + 0.1 ml delivery solution.
Animals were kept conscious throughout the procedure to ensure heart 
rate and blood pressure did not decrease significantly. A restraining can-
ister was used to control movement of mice. Tails were heated in a water 
bath (40°C) prior to injections for approximately 30 seconds to induce vein 
dilation for visualization and optimal injection.
The injection was performed with a 26-gauge, one-half inch needle in the 
ventral tail vein at the distant end of the tail. The complete volume minus 
0.1 ml of void volume held within the syringe was dispensed into the tail 
vein within 4 to 7 seconds at a constant rate to achieve maximum in vivo 
delivery. Animals were observed until recovery.
For hTVI experimental procedures, 7-week-old male Tg and WT mice 
were randomly allocated to groups (n = 10 per group) as follows: WT place-
bo-treated EV; WT 1.5 mg corticosterone-treated EV; WT placebo-treated 
wtOCN plasmid; WT 1.5 mg corticosterone-treated wtOCN plasmid, WT 
placebo-treated μOCN plasmid; WT 1.5 mg corticosterone-treated μOCN 
plasmid; 10 WT mice were allocated to a placebo-treated GFP plasmid 
group. All mice were treated with either 1.5 mg corticosterone or placebo for 
28 days as above, and hTVIs were performed on day 8. Mice were sacrificed 
on day 28, and organs were removed for ex vivo examination of parameters 
as discussed below. Blood was collected weekly from all mice and just prior 
to sacrifice (t = 28 days) for osteocalcin determinations. Weight was moni-
tored weekly throughout the experimental period and just prior to sacrifice.
Gene expression analysis. PCR was performed on DNase-treated total RNA 
extracted from whole mouse tibia, muscle, liver, and adipose tissue col-
lected from the gonadal fat pads using TRIZOL reagent (Invitrogen) and 
QIAGEN RNeasy mini-kits following sacrifice at day 28. RNA was con-
verted to cDNA using SuperScript III (Invitrogen), and amplification of 
osteocalcin was performed on an Eppendorf thermo-cycler with Taq SYBR 
Green Supermix to determine the presence of osteocalcin in the livers of 
hTVI-transfected mice using the following primers: (forward) 5′-GCTCT-
GTCTCTCTGACCTCACA-3′ and (reverse) 5′-TAGATGCGTTTGTAGG-
CGG-3′. 18S was used as an internal reference as described previously (57). 
Real-time quantitative PCR was used for the determination of fold changes 
of Hsd11b1, Fabp4, Pparg, Cebpa, Gilz, and Fkbp5 in adipose, tibia, muscle, 
and liver tissue using the primers described in Table 1. Once again, 18S was 
used as an internal reference as described previously (57).
Measurement of total and uncarboxylated serum osteocalcin. Blood was col-
lected by retro-orbital capillary puncture on anesthetized mice. Total 
osteocalcin was measured using radioimmunoassay (IRMA) reagents from 
Immunotopics according to manufacturer’s instructions. Uncarboxylated 
osteocalcin was measured as described previously (58). In short, serum 
samples were diluted to an osteocalcin concentration of 40 ng/ml. After 
incubation with 50 mg/ml hydroxyapatite (Calbiochem/EMB Sciences) 
for 1 hour at room temperature, the samples were centrifuged for 2 min-
utes at 10,000 g. Carboxylated osteocalcin binds to the hydroxyapatite. The 
amount of (nonbound) uncarboxylated osteocalcin was determined in the 
the first intron of the rat Pro-a1(I) collagen (Col1a1) gene was cloned with 
the rat Hsd11b1 cDNA, leading to expression in osteoblasts, were donated 
by Barbara Kream (University of Connecticut Health Center, Farmington, 
Connecticut, USA) (26). These mice were crossed with outbred CD-1 mice, 
resulting in an equal distribution of Tg mice overexpressing 11b-HSD2 in 
osteoblasts and WT littermates. The presence of Hsd11b2 transgene was 
tested by PCR of DNA obtained from toe clips (10). Mice were housed 
up to 5 per cage, maintained under Physical Containment Level 2 labora-
tory conditions, and had access to water and feed ad libitum except when 
fasting conditions were required. All animal procedures were approved by 
the Sydney South West Area Health Services Ethical Committee.
For initial WT versus Tg animal experiments, 8-week-old male Col2.3-
11bHSD2 Tg mice (n = 42) and WT littermates (n = 44) were subcutaneously 
implanted with slow-release pellets containing either 1.5 mg corticoster-
one or placebo (Innovative Research of America). Following a previously 
described protocol (55), pellets were implanted at days 0, 7, 14, and 21 in 
order to achieve continuous suppression of osteoblast function (as indi-
cated by a sustained reduction in serum osteocalcin levels) (55). At day 1 
after implantation, serum corticosterone levels peaked at 536 ± 85 nmol/l 
and 489 ± 79 nmol/l in corticosterone-treated WT and Tg mice, respectively, 
while serum corticosterone levels remained low in placebo-treated WT and 
Tg animals, at 149 ± 43 and 171 ± 37 nmol/l, respectively. Serum corticoster-
one was measured by stable isotope dilution liquid chromatography–tan-
dem mass spectrometry (LC-MS/MS) as described previously (56).
Body mass analysis — PIXImus. Measurements of lean and fat mass were 
performed on a Lunar PIXImus Densitometer for mice (GE Medical 
Systems) at weekly intervals and just prior to sacrifice according to the 
manufacturer’s instructions.
ITTs. For ITTs, mice were fasted for 6 hours prior to a baseline blood 
glucose reading, followed by an intraperitoneal injection of insulin at 0.75 
U/kg body weight (Eli Lilly). Blood glucose was then measured at 15, 30, 
60, 90, and 120 minutes after insulin injection. Blood was obtained from a 
tail prick, and blood glucose was measured on glucose strips and an Accu 
check glucometer (Roche). Blood glucose data is presented as percentage 
of baseline blood glucose.
oGTTs. oGTTs were performed following a 6-hour fast by measuring 
blood glucose on glucose strips and an Accu-check glucometer (Roche) 
at baseline and at 15, 30, 60, 90, and 120 minutes after oral bolus dose of 
glucose at 2 g/kg body weight. Blood was obtained as for the ITTs. Blood 
glucose data is presented as percentage of baseline blood glucose.
Gene therapy — tail vein injection. OC and mutant OC (the 3 glutamic 
acid residues, Glu [positions], had been mutated to aspartic acid resi-
dues [Asp]) constructs were provided by Caren Gundberg (33). pLIVE 
expression vector, a vector driven by a liver-specific promoter composed 
of the minimal mouse albumin promoter and the mouse α-fetoprotein 
enhancer was purchased from Mirus Bio. To obtain liver expression of 
osteocalcin, a full-length OC and mutant OC was inserted into the pLIVE 
Table 1
Primers used for qRT-PCR
Gene Forward Reverse
Hsd11b1 5′-GCTCACTACATTGCTGGCAC-3′ 5′-GGAGATGACGGCAATGCT-3′
Fabp4 5′-CTCACCTGGAAGACAGCTCC-3′ 5′-TCACCTTCCTGTCGTCTGC-3′
Pparg 5′-TTTTCCGAAGAACCATCCGAT-3′ 5′-ACAAATGGTGATTTGTCCGTTG-3′
Cebpa 5′-GATAAAGCCAAACAACGCAACG-3′ 5′-CTAGAGATCCAGCGACCCGAA-3′
Gilz 5′-CTCGTGAAGAACCACCTGATG-3′ 5′-ACTTACACCGCAGAACCACC-3′
Fkbp5 5′-AAAGCCGTGGAGTGCTGCGA-3′ 5′-CGAGCGGCCCTGTTCTGAGG-3′
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Western blotting. Cells were lysed in ice-cold lysis buffer (50 mM Tris, 
150 mM NaCl, 0.1% SDS, 1% v/v Triton X-100, 100 mM NaF, Complete 
Protease Inhibitor tablet [Roche], phosphatase inhibitor tablet [Phos-
STOP, Roche], pH 7.8). Protein concentrations were determined by Micro 
BCA assay (Pierce). Equal amounts of protein were subjected to electro-
phoresis on ready-made NuPage Bis-Tris gels (4%–12%; Invitrogen) and 
then transferred electrophoretically onto a nitrocellulose membrane. 
Immunoblotting was performed according to the manufacturer’s instruc-
tions for each antibody. Bands were identified using a Kodak Imaging sys-
tem, using an enhanced chemiluminescent substrate (Western Lightning; 
PerkinElmer), and band densities were measured by densitometry using 
Kodak Molecular Imaging Software. Density ratios were calculated using 
Quantity One (Bio-Rad Laboratories). All antibodies were purchased from 
Santa Cruz Biotechnology Inc., except for P-InsR (Y1150), which was pur-
chased from Cell Signalling.
Statistics. All results are presented as mean ± SEM. A 1-way ANOVA, 
followed by Fisher’s PLSD post-hoc test, was used to determine signifi-
cant differences between groups when data were parametric. Interactions 
between the genotype or vector and corticosterone treatment were deter-
mined by a 2-way ANOVA. Repeated-measures ANOVA were used to deter-
mine statistical significance within groups over time. A P value of less than 
or equal to 0.05 was considered significant. StatView 5.0 software (SAS 
Institute Inc.) was used for all analyses.
Study approval. All animal procedures were approved by the Sydney South 
West Area Health Services Ethical Committee.
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supernatant using radioimmunoassay (IRMA) reagents as described above. 
Subsequently, the total amount of uncarboxylated osteocalcin was calcu-
lated using the dilution factor.
Measurement of serum corticosterone. Serum corticosterone was measured 
by stable isotope dilution LC-MS/MS as described previously (56).
Oil Red O staining. Livers were excised from mice at the end of the 28-day 
experimental period. 6- × 5- × 5-mm segments were then cut from the 
whole livers and fixed in 10% buffered formalin for 24 hours before being 
soaked in 30% sucrose for 48 hours at 20°C. Liver segments were then 
embedded in OCT compound (Tissue-Tek), and 10-μm sections were 
mounted on poly-l-lysine–coated slides. Sections were then air-dried, fixed 
with formalin, and stained with Oil Red O in 60% isopropanol to observe 
lipid deposition. ImageJ analysis software (NIH) was used to determine 
Oil Red O–positive area as a percentage of total area. Positive areas were 
determined using the default color threshold method, followed by applica-
tion of the particle analysis tool, which determined whether an area (which 
could be as small as 1 × 1 pixels) was staining or not. The total sum of all 
these positive areas in a determined area (in our case, in a micrograph) 
was then calculated and expressed as a percentage of the total area. Three 
sections per mouse were analyzed.
Adipose tissue histology. Gonadal fat pads were used to evaluate adipose tis-
sue. Fat pads were excised from mice at the end of the 28-day experimental 
period and fixed with 4% paraformaldehyde, embedded in paraffin, sec-
tioned at 7 μm, stained with H&E, and evaluated by histomorphometry at 
×200 magnification. Histomorphometric measurements were performed 
using Osteomeasure software (Osteometrics Inc.).
Isolation of primary hepatocytes. Hepatocytes were isolated from mice that 
had received hTVI of EV, wtOCN, or μOCN 28 days prior to the cell isolation 
procedure. Liver perfusions were carried out on anesthetized mice and per-
formed by cannulation of the portal vein on anesthetized mice; outflow was 
directed through cutting of the inferior vena cava. Perfusion medium con-
taining Liberase (Roche) enzyme cocktail mix was used to digest the connec-
tive tissue, and, after 10 minutes of perfusion, whole livers were transferred 
to a petri dish in which livers were manually dissociated. The cell suspension 
was filtered through a 70-μm cell filter, centrifuged at 60 g for 2 minutes at 
4°C, and resuspended in 50 ml PBS 5 times. On the final centrifugation, cells 
were resuspended in 50 ml RPMI plus 5% BSA, and cells were counted on a 
hemocytometer. For GFP expression, cells were seeded in collagen-coated 
chamber well slides (250,000 cells per chamber) and incubated in cell cul-
ture medium (5% BSA, RPMI-40) under a humidified atmosphere (37°C, 
95% O2/5% CO2) for 24 hours before fixing and counterstaining with DAPI.
For protein analysis, cells were plated into collagen-coated 6-well plates 
(4 × 106 cells per well) and incubated in cell culture medium (5% BSA, 
RPMI-40) under a humidified atmosphere (37°C, 95% O2/5% CO2). After 
2-hour incubation, cells were washed and cell medium changed (RPMI-
40 serum free). Following 24-hour incubation, the cells were treated 
with either placebo or corticosterone at a concentration of 10–8 M. After 
24 hours of treatment, cells were treated with insulin (50 nM insulin in 
serum-free RPMI-40 medium) or vehicle for 5 minutes and washed with 
PBS. Cells were collected in ice-cold PBS (500 μl), and cells from the same 
treatment group were pooled and centrifuged (3 minutes, 3,000 g). Cell 
pellets were resuspended in lysis buffer (50 mM Tris, 150 mM NaCl, 100 
mM NaF, 0.1% w/v SDS, 1% v/v Triton X-100, and Roche protease inhibitor 
and phosphatase inhibitor), left on ice for 30 minutes, and centrifuged 
(5 minutes, 0°C–4°C, 17,500 g). The lysates were collected and protein con-
centration was determined using a BCA.
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